The use of ACE inhibitors or ARBs was substantially greater among participants with CKD (73.2% vs. 40.2%), and SGLT2i use was also higher (15.5% vs. 11.3%), while GLP‐1 receptor agonist use remained low in both groups (3.5% vs. 2.5%). Here, ACE is linked to chronic kidney disease.